2,928 results on '"Litzow, Mark R."'
Search Results
202. Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
203. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
204. Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
205. Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia
206. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
207. Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia
208. Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
209. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
210. A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
211. Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms
212. Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
213. A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
214. Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
215. Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
216. Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
217. PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
218. Comparison between GATA2 and DDX41-mutated myeloid neoplasms
219. Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib
220. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
221. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
222. Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
223. Improved accuracy of acute graft-versus-host disease staging among multiple centers
224. Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
225. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
226. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
227. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
228. Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
229. Incorporating Immunotherapy into Upfront ALL Therapy
230. BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients
231. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
232. Immunophenotypic and molecular comparison between allogeneic and autologous graft‐vs‐host disease of the skin: A retrospective study using immunohistochemical and proteomics methods
233. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
234. Momelotinib therapy for myelofibrosis: a 7-year follow-up
235. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
236. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
237. Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis
238. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia
239. A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy
240. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
241. Providing Personalized Prognostic Information for Adult Leukemia Survivors
242. Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation
243. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research
244. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
245. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization
246. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
247. Blood and Marrow Transplantation
248. Acute Leukemia
249. Disparities in Trial Enrollment and Outcomes of Hispanic Adolescent and Young Adult Acute Lymphoblastic Leukemia
250. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.